Embecta Corp's Q1 2026 Earnings Call Highlights: Strategic Progress Amidst Market Challenges.

Embecta Corp (EMBC) Q1 2026 earnings call highlights strategic progress amid market challenges. The company has successfully transitioned over 95% of its US and Canadian revenue to the Embecta brand, expanded its portfolio with market-appropriate pen needles and syringes, and made significant progress in its GLP-1 strategy. However, the US business saw a year-over-year decline of 7.6%, driven by lower pricing and volumes, and the company faces incremental pricing headwinds in the US.